Familial Amyloid Caused by Mutant Gelsolin
Familial amyloidosis caused by mutant gelsolin (familial amyloidosis, Finnish type, or FAF), also known as Meretoja syndrome, is an extremely rare autosomal dominant condition within the group of hereditary systemic amyloidoses. It results from mutations in the GSN gene, which encodes the protein gelsolin. The mutant protein is cleaved abnormally, and the fragments build up as gelsolin amyloid fibrils (AGel) in connective tissue, blood vessel walls, peripheral nerves and the skin.
One of its most characteristic and disfiguring features is early-onset loose, sagging facial skin (cutis laxa), together with cranial nerve palsies (especially of the facial nerve, cranial nerve VII), lattice corneal dystrophy and chronic structural changes in the skin.
At Haute-Derma, we manage gelsolin amyloidosis as a multidisciplinary condition: molecular genetic screening, coordinated care for neurological and eye complications, and non-invasive tissue regeneration and lifting technologies, all aimed at improving both quality of life and appearance as much as possible.
Molecular Pathophysiology: GSN Mutations and AGel Fibril Formation
Gelsolin is a calcium-dependent, actin-severing protein that remodels the cell's internal skeleton. In FAF/Meretoja syndrome, damage unfolds through a chain of biological events:
- Point mutation in GSN: The most common is c.640G>A, which swaps aspartate for asparagine at position 187/214 of the protein (D187N/D98N).
- Aberrant proteolysis: The altered structure lets the enzyme furin cut mutant gelsolin prematurely inside the cell, producing a C68 fragment. Once secreted into the extracellular space, this fragment is cut again by MT1-MMP into 8-kDa and 5-kDa pieces that self-assemble into AGel amyloid fibrils.
- Infiltration and destruction of the elastic network: AGel fibrils pack densely around elastic fibers and the skin's basement membrane and trigger release of matrix metalloproteinases (MMPs) that destroy the skin's elasticity, producing cutis laxa.
Systemic Features and Cutis Laxa–Type Skin Changes
Changes caused by gelsolin mutations usually begin between ages 20 and 40 and progress steadily over time:
Skin and Facial Features (Cutis Laxa Phenotype)
- Sagging skin and deep wrinkles (premature aging): Skin on the forehead, cheeks, chin and neck loses its ability to spring back and hangs in deep, permanent folds, making patients look much older than their age.
- Drooping eyelids (ptosis) and ectropion: Very lax upper-lid skin combined with weakness of the orbicularis muscle makes the lids droop and block vision. The lower lids tend to turn outward, causing constant tearing.
- Dry skin, visible vessels and easy bruising: Small skin vessels loaded with AGel become fragile and bleed under the skin after minor trauma.
Associated Neurological and Eye Features
- Peripheral facial nerve palsy: Weakness develops slowly, usually starting in the forehead and around the eyes, and eventually leads to loss of facial expression on both sides.
- Lattice corneal dystrophy type II (LCD II): AGel deposits form lattice-like lines beneath Bowman's layer of the cornea, causing reduced vision, glare and recurrent corneal erosions.
- Peripheral neuropathy: Numbness and tingling in a "glove-and-stocking" pattern in the limbs, caused by AGel deposits around nerve sheaths.
Screening and Confirmatory Diagnosis at Haute-Derma
- Histopathology and Congo red: A biopsy from lax skin shows amorphous deposits around elastic fibers, sweat gland basement membranes and vessel walls. Congo red staining shows apple-green birefringence under polarized light.
- Immunohistochemistry (IHC): Monoclonal anti-gelsolin antibodies clearly distinguish AGel from AL (light-chain) amyloid and keratin-derived (AK) amyloid.
- Molecular genetic testing: Sequencing the GSN gene from a blood sample is the gold standard for confirming Meretoja syndrome and for family genetic counseling.
Management and Aesthetic Restoration at Haute-Derma
There is currently no gene therapy that cures GSN mutations. Our plan at Haute-Derma therefore focuses on slowing skin breakdown, preserving nerve and eye function, and restoring facial contour:
Medical Management and Skin Protection
- Managing dry eye and eyelid weakness: High-viscosity artificial tears and a protective corneal gel at night prevent corneal ulcers when the lids do not close fully.
- Protecting the elastic framework: Low-strength topical retinoids combined with bioactive peptides stimulate new collagen to make up for lost elastin.
Non-Invasive Rejuvenation and Lifting
- Micro-focused ultrasound (HIFU/Ultherapy): Heat delivered to the SMAS layer prompts lax facial tissue to contract, helping to support the cheeks and jowls.
- Tissue-restoring injections (BAP technique with concentrated hyaluronic acid): Deeply hydrate the skin and stimulate fibroblasts to rebuild dermal matrix degraded by AGel deposits.
Functional and Aesthetic Reconstructive Surgery
- Eyelid surgery (blepharoplasty): Removes excess upper-lid skin to clear the visual field and corrects lower-lid ectropion to protect the eye.
- Brow suspension and partial facelift: Improve facial appearance and relieve the muscular strain caused by lax skin.
